ACRS (Aclaris Therapeutics) Research & Development: $56.72 Mil (TTM As of Mar. 2026)


ACRS Aclaris Therapeutics Inc ACRS
38 GF Score
Price $4.89
GF Value $0.45
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Research & Development?

Aclaris Therapeutics ACRS +1.77% 38 Research & Development is $56.72 Mil as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aclaris Therapeutics's Research & Development for the three months ended in Mar. 2026 was $15.66 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $56.72 Mil.

Aclaris Therapeutics  (NAS:ACRS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aclaris Therapeutics Research & Development Related Terms

Aclaris Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Research & Development Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.81 77.81 98.38 33.59 52.65

Aclaris Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.58 11.45 13.03 16.58 15.66
ACRS
38GF Score
Aclaris Therapeutics Inc ACRS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $56.72 Mil mean?
Aclaris Therapeutics (ACRS) has a Research & Development of $56.72 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Research & Development too high?
Aclaris Therapeutics' current Research & Development is $56.72 Mil. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Research & Development compare to IMMX and PRME?
Aclaris Therapeutics' Research & Development of $56.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Research & Development is $56.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $4.89 — trading 985.6% above its estimated fair value. The current Research & Development is $56.72 Mil. Aclaris Therapeutics' overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Research & Development is $56.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $4.89 is trading 985.6% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Research & Development: $56.72 Mil
  • GF Value™: $0.45 vs. price of $4.89 (985.6% above fair value)
  • GF Score™: 38/100 with 9 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score

Get the complete analysis for ACRS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.89
Price
$0.45
GF Value